Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosaprepitant - Merck & Co

Drug Profile

Fosaprepitant - Merck & Co

Alternative Names: Emend For Injection; Emend IV; Fosaprepitant dimeglumine; IVEmend; MK-0517; MK-517; ONO-7847; Proemend

Latest Information Update: 11 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; Ono Pharmaceutical
  • Class Antiemetics; Fluorinated hydrocarbons; Morpholines; Phosphonic acids; Small molecules; Triazoles
  • Mechanism of Action Neurokinin 1 receptor antagonists; Substance P inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting
  • No development reported Postoperative nausea and vomiting

Most Recent Events

  • 03 Jul 2019 Merck Sharp & Dohme initiates a phase IV trial in Chemotherapy-induced nausea and vomiting (In infants, In children, In adolescents) in Hungary (EudraCT2018-004844-43)
  • 24 Jun 2018 Biomarkers information updated
  • 23 Mar 2018 The Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion for Chemotherapy induced nausea and vomiting (In infants, In children, In adolescents) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top